AMA Publishes Category I CPT Code for Trans-Orifice Esophagogastric Fundoplasty

Israel based developer of minimally invasive endosurgical tools and a leader in direct visualization technology, Medigus Ltd.says the American Medical Association (AMA) has created a new Category 1 Current Procedural Terminology (CPT®) code for Esophagogastric Fundoplasty Trans-Orifice Approach procedures which Medigus anticipates would be the code used for its MUSE(TM) platform.


Medigus is a pioneer developer of a unique proprietary endoscopic device, the MUSE(TM) system, to treat gastroesophageal reflux disease (GERD), one of the most common chronic diseases in the western world. The company’s MUSE system incorporates its revolutionary micro ScoutCam technology. CPT codes are descriptive terms physicians use for reporting all medical, surgical, and diagnostic services and procedures; Category I codes are most frequently used by healthcare providers when reporting a significant portion of their services. In order to be granted a Category I code, an application must go through a rigorous sequential review and approval process by key members of the medical community who evaluate the procedure’s value to physicians and patients.

The recommendation will now be reviewed by the Relative Value Committee (RUC) in April, which will further assess the value for physician payment levels under Medicare. Approvals are scheduled to be finalized in November, and the new code is expected to take effect on January 1, 2016.

The code, 432XX1, will enable physicians to specifically communicate information to payers about the procedure which is used to treat the underlying anatomical cause of chronic Gastroesophageal Reflux Disease (GERD).

Company comments

“This Category 1 CPT code represents an important step in establishing coverage for this kind of procedure. We are pleased with the AMA’s recommendation and would like to thank the AGA, ACG, ASGE and SAGES for their leadership, which indicates the medical community’s recognition of the need for alternative and minimally invasive procedures for chronic GERD patients,” said Chris Rowland, CEO of Medigus. “The Category I code should enhance access to these procedures which were created to help enhance both patient care and outcomes.”

Source: Globe Newswire

Share your thoughts

Your email address will not be published. Required fields are marked *